Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Real-World Data Could Help Inform Treatment Sequencing Decisions in HR+/HER2- Breast Cancer

October 24th 2022

Megan Kruse, MD, discusses the evolving treatment landscape in HR-positive, HER2-negative breast cancer, how the approval of fam-trastuzumab deruxtecan-nxki has affected sequencing choices in HER2-positive disease, and the importance of addressing racial disparities in breast cancer care.

Stark Differences in Mortality Rates Emphasize Ongoing Racial Disparities in Breast Cancer

October 24th 2022

Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.

Adjuvant Palbociclib Plus ET Does Not Prolong IDFS Over ET Alone in Stage IIA ER+ Breast Cancer

October 19th 2022

The addition of palbociclib to adjuvant endocrine therapy (ET) failed to improve invasive disease-free survival over ET alone in patients with estrogen receptor–positive, HER2-negative early breast cancer.

Experts Navigate the New World of HER2-Positive Metastatic Breast Cancer

October 19th 2022

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

Dr. Jain on the Benefit of CDK7 Inhibitors in HR+ Breast Cancers

October 18th 2022

Amit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.

Treatment for HR+ Metastatic Breast Cancer After Progression on CDK4/6 Inhibitors

October 18th 2022

Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.

HR+ Metastatic Breast Cancer: Continuing CDK4/6 Inhibition Beyond Progression

October 18th 2022

Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.

Dr. Kalinsky on Chemotherapy for Premenopausal Patients With HR+/HER2- Breast Cancer

October 13th 2022

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

Abemaciclib Dose Reductions Lead to Prolonged Treatment in HR+/HER2- Breast Cancer

October 13th 2022

Abemaciclib produced a clinically manageable safety profile in patients with hormone receptor–positive, HER2-negative, early breast cancer or advanced breast cancer, and dose reductions were found to effectively mitigate discontinuation.

Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric Cancer

October 13th 2022

Shared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.

Novel Clinical Trials With ADCs in Gastric Cancer

October 13th 2022

Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.

FDA Grants Priority Review to Sacituzumab Govitecan for Pretreated HR+/HER2- Metastatic Breast Cancer

October 11th 2022

The FDA has accepted and granted priority review to a supplemental biologics license application for sacituzumab govitecan for the treatment of with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer after endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.

Dr. Kruse on the Effects of the MAINTAIN Trial on HR+/HER2- Breast Cancer Treatment

October 11th 2022

Megan Kruse, MD, discusses the real-world effects of the phase 2 MAINTAIN trial on treatment in advanced hormone receptor–positive, HER2-negative breast cancer.

Cost Minimization Relies on Sequencing in Metastatic Breast Cancer

October 11th 2022

Sequencing complexities with chemotherapy-based regimens in metastatic breast cancer pose unique challenges for valuebased decision-making in routine practice.

Dr. Hewitt on Considerations for Conservation Vs Mastectomy in Breast Cancer

October 11th 2022

Kelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.

Interpreting Data With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

October 11th 2022

In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.

Brief Review of SERM Therapy Data in HR+ Metastatic Breast Cancer

October 11th 2022

Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].

Dr. Goetz on the Clinical Significance of Lasofoxifene in ER+/HER2- Breast Cancer

October 7th 2022

Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.

Neoadjuvant Pegylated Liposomal Doxorubicin Regimen Has Promising Efficacy in HER2+ Breast Cancer

October 7th 2022

The combination of pegylated liposomal doxorubicin, cyclophosphamide, trastuzumab, and pertuzumab elicited encouraging responses with acceptable safety when given as neoadjuvant treatment in patients with HER2-positive breast cancer.

Trastuzumab Deruxtecan Expands Metastatic Breast Cancer Treatment Landscape Across HER2-Expressing Subtypes

October 7th 2022

Jane Lowe Meisel, MD, discussed the emergence of HER2-low as a new category in breast cancer, outlining the significance of the phase 3 DESTINY-Breast04 trial and the unique qualities of trastuzumab deruxtecan in the HER2-positive and HER2-low populations.